Navigation Links
New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
Date:10/17/2008

oup, reports of nausea fell to 13% after 8-10 weeks of treatment and remained above 10% for more than 20 weeks.

Other common gastrointestinal-related adverse events with liraglutide were diarrhea, vomiting and dyspepsia.

Patients on both treatments lost weight during the study. Weight reduction in patients on liraglutide was also consistently seen in the LEAD(TM) 3a studies.

Key LEAD(TM) 6 data:

Liraglutide 1.8 mg QD + Exenatide 10 micrograms, BID +

metformin and/or SU metformin and/or SU

N=233 N=231

Diabetes duration,

years at baseline 8.5 7.9

BMI, kg/m(2) at

baseline 32.9 32.9

HbA1c, % at baseline 8.2 8.1

Change in HbA1c % (SE)

from baseline -1.12* (0.08) -0.79 (0.08)

% HbA1c <7.0% 54* 43

% HbA1c less than or

equal to 6.5% 35* 21

Weight change, kg from

baseline -3.24 -2.87

% Change in HOMA-B

from baseline 32.1* 2.7

Change FPG (fasting plasma glucose)

mmol/L from baseline -1.61* -0.60

Minor hypoglycemic

events/subject/year 1.9* 2.6

*P<0.05

About liraglutide

Once-daily liraglutide is the first human glucagon-like peptide-1 (GLP-1) analog developed for the treatment of type 2 diabetes. Liraglutide works by stimulating the release of insulin and inhibiting the release of glucagon from the liver afte
'/>"/>

SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. Phase III Trial Finds Pharmaxis Bronchitol Effective
7. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
8. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
9. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Product and process impurities in biopharmaceuticals ... are often “lost in the noise,” making their ... Dr. Rowel Tobias, Senior Scientist, Protein Chemistry at ... Quality at Nanotherapeutics, Inc., to lear about a ... and quantitation while achieving the required specificity and ...
(Date:7/10/2014)... Cleveland, Ohio (PRWEB) July 10, 2014 ... in ion channel-expressing cell lines, and the gap that ... new cells that expand its industry-leading portfolio of validated ... focuses on ion channel-expressing cell lines, as ion channels ... able to control this activity creates the potential to ...
(Date:7/10/2014)... 10, 2014 Unraveling life’s mysteries can ... The Archer Family purchased a DNA test ... ended up with a lifetime of memories, sharing, and ... family members’ DNA genuinely brought the family closer together. ... deeper into genetic history and prior to taking the ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 OMICS Group’s ... techniques during 18-20 August, 2014 at Double Tree by ... the recent developments in Analytical & Bioanalytical research methods ... , Speaking on this occasion, Dr. Srinubabu Gedela, MD ... Acta conference is a remarkable one in bringing a ...
Breaking Biology Technology:Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
... Nov. 29 Martek Biosciences,Corporation (Nasdaq: MATK ... at,the upcoming ThinkEquity Partners ThinkGreen Conference in San ... 2007 at the St. Regis Hotel.,Steve Dubin, CEO, ... at 3:00,p.m. PST., A live audio webcast ...
... clinicians from Harvard, Stanford, University of, Washington, the Scripps ... Hospital partner with ... embryonic stem cells, by using pharmaceutical medicines to modulate stem ... and via the use of ,reprogrammed, adult stem ...
... 29 , - The Swiss Anecova Selected, ... the 39 visionary companies,selected as Technology Pioneers 2008. ... of them. The Technology Pioneers 2008 were nominated ... companies, academics and media. The final selection from ...
Cached Biology Technology:Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies 2Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies 3Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies 4Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies 5The World Economic Forum Announces Technology Pioneers 2008 2The World Economic Forum Announces Technology Pioneers 2008 3
(Date:7/10/2014)... 2, 2014  Unisys Corporation,s (NYSE: UIS ) ... N.V., today announced that it has been selected by the ... a new Basic Provision Biometrics solution for penitentiaries across ... the contract with a solution based on its open standards-based ... of the contract is up to seven years, with the ...
(Date:7/10/2014)... 2014 NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused ... Gino Pereira was interviewed on July 1 st ... Florida . Mr. Pereira discusses the company,s next generation ... and how the Wocket™ aims to replace a traditional wallet ... Cedric Harris tells Gino he has never heard of ...
(Date:7/10/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/h7h8lq/gesture ... "Global Gesture Recognition & Touch-Less Sensing (2D, 3D, ... report to their offering ... & Touch-Less Sensing Market to Grow Exponentially. Touch-less ... but the companies were unable to leverage this ...
Breaking Biology News(10 mins):Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2
... detect a crippling disease called QPX occurring in clam beds ... Although it does not affect humans and it is not ... a significant impact on a local economy by killing ... QPX - for quahog parasite unknown - is a single-celled ...
... genome of a microbiological master of adaptationArchaea, small ... they are able to live under extreme environmental ... pH-values, or high temperatures. Nature's masters of adaptation, ... draw conclusions about the first organisms on earth. ...
... that restoring a gene often silenced in lung cancer causes ... new strategy for treating the disease. , The research ... or silenced in a large majority of lung cancers, and ... pancreas. The work was led by scientists at The Ohio ...
Cached Biology News:New genetic test can detect clam disease 2Life in deadly conditions 2Life in deadly conditions 3Restoring silenced suppressor gene kills lung-cancer cells 2
... Clear amber to slightly ... Contains 10 vials per set, each ... adjuvant homogenized in the following proportions ... Arlacel A (mannide monooleate emulsifier), and ...
For removal of the zona pellucida. Sterile, Mouse Embryo tested...
Imject Freund's Complete Adjuvant (FCA)...
... SYBR Safe DNA gel stain was developed specifically ... ethidium bromide for staining DNA in agarose or ... less mutagenic than ethidium bromide but SYBR Safe ... ethidium bromide. SYBR Safe stain comes as a ...
Biology Products: